Healthcare -
Medical - Healthcare Plans - NASDAQ - US
$ 2.935
3.6 %
$ 1.49 B
Market Cap
-72.0
P/E
1. INTRINSIC VALUE
Balance Sheet
Clover Health Investments, Corp.
| Current Assets | 343 M |
| Cash & Short-Term Investments | 222 M |
| Receivables | 92.8 M |
| Other Current Assets | 28.8 M |
| Non-Current Assets | 238 M |
| Long-Term Investments | 202 M |
| PP&E | 5.31 M |
| Other Non-Current Assets | 30.6 M |
| Current Liabilities | 214 M |
| Accounts Payable | 34.6 M |
| Short-Term Debt | 0 |
| Other Current Liabilities | 179 M |
| Non-Current Liabilities | 26.1 M |
| Long-Term Debt | 0 |
| Other Non-Current Liabilities | 26.1 M |
EFFICIENCY
Earnings Waterfall
Clover Health Investments, Corp.
| Revenue | 1.37 B |
| Cost Of Revenue | 1.01 B |
| Gross Profit | 365 M |
| Operating Expenses | 411 M |
| Operating Income | -45.7 M |
| Other Expenses | -2.74 M |
| Net Income | -43 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Clover Health Investments, Corp.
| Net Income | -43 M |
| Depreciation & Amortization | 1.33 M |
| Capital Expenditures | -1.56 M |
| Stock-Based Compensation | 114 M |
| Change in Working Capital | 12.9 M |
| Others | -28.6 M |
| Free Cash Flow | 33.3 M |
Wall Street Analysts Price Targets
Clover Health Investments, Corp.
Wall Street analysts predict an average 1-year price target for CLOV of $4.08 , with forecasts ranging from
a
low of
$1.8 to a high of $6 .
CLOV Lowest Price Target
Wall Street Target
1.8 USD
-38.67%
CLOV Average Price Target
Wall Street Target
4.08 USD
38.84%
CLOV Highest Price Target
Wall Street Target
6 USD
104.43%
4. DIVIDEND
ANALYSIS
CLOV does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Clover Health Investments, Corp.
Sold
0-3 MONTHS
858 K USD 2
3-6 MONTHS
1.2 M USD 3
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
1 M USD 1
9-12 MONTHS
7. News
Primary Care Physician Use of Counterpart Assistant Technology Linked to Better Health Outcomes in Patients with Chronic Obstructive Pulmonary Disease
New whitepaper shows that a relationship with a primary care physician (“PCP”) who uses Counterpart Assistant is correlated with more frequent Chronic Obstructive Pulmonary Disease (“COPD”) diagnosis, increased specialty care, and meaningful reductions in hospitalizations (15% lower) and 30-day readmissions (18% lower).
globenewswire.com
- 2 days ago
Clover Health Pre-Q2 Earnings Analysis: Buy, Sell or Hold the Stock?
CLOV's second-quarter results are likely to reflect strong Medicare Advantage membership growth and expansion and deeper integration of Clover Assistant.
zacks.com
- 5 days ago
Clover Health Applauds White House and CMS' Push to “Tear Down Digital Walls,” Accelerating and Simplifying Access to Health Data for Patients and Their Clinicians
WILMINGTON, Del., July 31, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover Health”), a physician enablement company bringing access to great healthcare to everyone on Medicare, strongly supports the White House and Centers for Medicare & Medicaid Services' (CMS) announcement calling on the healthcare industry to “tear down digital walls” and build a truly patient-centric, interoperable ecosystem.
globenewswire.com
- 6 days ago
Counterpart Health Appoints Vicky Bruner as Vice President of Operations to Support Expansion and Customer Execution
WILMINGTON, Del., July 29, 2025 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. (“Counterpart”), a wholly owned subsidiary of Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”) and a leading AI-powered physician-enablement platform, today announced the appointment of Vicky Bruner as Vice President of Operations.
globenewswire.com
- 1 week ago
OSCR vs. CLOV: Which Stock Is A Better Buy Now?
In this piece, we'll check in on two mid-cap health insurance plays that are leveraging their tech-savvy and digital strengths to grab a bigger slice of the health insurance industry.
247wallst.com
- 1 week ago
TotalEnergies - Angola: Start-up of BEGONIA and CLOV Phase 3 Offshore Projects
PARIS--(BUSINESS WIRE)--TotalEnergies (Paris:TTE) (LSE:TTE) (NYSE:TTE) announces the start of production from the BEGONIA and CLOV Phase 3 offshore projects, leveraging ullage in the PAZFLOR and CLOV floating production, storage and offloading units (FPSO) to add a total of 60,000 barrels a day of new production. These two subsea tie-back projects deliver additional production leveraging available capacity on existing FPSO's and as such have low marginal costs and low carbon intensities. BEGONI.
businesswire.com
- 2 weeks ago
Clover Health to Participate in Upcoming Canaccord Genuity 45th Annual Growth Conference
WILMINGTON, Del., July 21, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that its Chief Financial Officer, Peter Kuipers, will present at the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025, at 11:00 a.m. Eastern Time.
globenewswire.com
- 2 weeks ago
Clover Health Appoints Joseph Oldakowski as Vice President of Finance and Controller
WILMINGTON, Del., July 17, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover Health”), a physician enablement company bringing access to great healthcare to everyone on Medicare, today announced the appointment of Joseph (Joe) Oldakowski as Vice President of Finance and Controller. In this role, Mr. Oldakowski reports to Chief Financial Officer Peter Kuipers and will lead Clover's corporate accounting, GAAP, SEC, and statutory financial reporting and tax function.
globenewswire.com
- 2 weeks ago
Clover Health Launches New Jersey Community Pharmacy Program in Partnership with IPC's iCare+ Network
WILMINGTON, Del., July 09, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover Health”), a leading Medicare Advantage company committed to affordable, high-quality care, today announced the launch of a new community-based pharmacy pilot program across New Jersey.
globenewswire.com
- 4 weeks ago
Clover Health to Report Second Quarter 2025 Financial Results on August 5, 2025
WILMINGTON, Del., July 08, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that it will release its financial results after the market closes on Tuesday, August 5, 2025. Company management will host a conference call and webcast at 5:00 p.m. Eastern Time on the same day to discuss the company's business and financial performance for the quarter.
globenewswire.com
- 4 weeks ago
Clover Health Set to Join Russell 3000® Index
WILMINGTON, Del., June 30, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover Health”), announced that it is set to join the broad-market Russell 3000® Index, effective after the US market opens today, June 30, 2025, as part of the 2025 Russell indexes reconstitution.
globenewswire.com
- 1 month ago
All You Need to Know About Clover Health Investments (CLOV) Rating Upgrade to Strong Buy
Clover Health Investments (CLOV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
zacks.com
- 2 months ago
8. Profile
Summary
Clover Health Investments, Corp. CLOV
COUNTRY
US
INDUSTRY
Medical - Healthcare Plans
MARKET CAP
$ 1.49 B
Dividend Yield
0.00%
Description
Clover Health Investments, Corp. operates as a medicare advantage insurer in the United States. The company through its Clover Assistant, a software platform that provides preferred provider organization and health maintenance organization health plans for medicare-eligible consumers. It also focuses on non-insurance businesses. Clover Health Investments, Corp. was incorporated in 2014 and is based in Franklin, Tennessee.
Contact
725 Cool Springs Blvd, Franklin, TN, 37067
https://www.cloverhealth.com
IPO
Date
June 12, 2020
Employees
570
Officers
Ms. Rachel Fish
Chief People Officer
Mr. Andrew Toy
Co-Founder, Chief Executive Officer & Director
Ms. Wendy Richey
Chief Compliance Officer
Dr. Kumar Dharmarajan
Chief Medical Officer of Clover Assistant
Ms. Karen Soares
General Counsel, Senior Vice President & Corporate Secretary
Ms. Jamie L. Reynoso
Chief Executive Officer of Medicare Advantage
Mr. Vivek Garipalli
Co-Founder & Executive Chairman
Mr. Peter J. Kuipers
Chief Financial Officer
Mr. Brady Priest J.D.
Chief Executive Officer of Home Care
Mr. Conrad Wai
Chief Executive Officer of Counterpart Health